Survival rates of men with prostate cancer might soon be increased with a new vitamin E (known as tocotrienol or T3) treatment which could significantly reduce tumour regrowth.
Existing chemotherapy and hormonal therapy treatment of prostate cancer was insufficient because it failed to kill off the prostate cancer stem cells which were believed to be responsible for the regrowth of tumours. However, the research team have discovered a particular form of T3, called gamma-tocotrienol (γ-T3), can successfully kill off the prostate cancer CSCs.